Literature DB >> 8660572

Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease.

E Bianchi1, C Steinkühler, M Taliani, A Urbani, R De Francesco, A Pessi.   

Abstract

Hepatitis C virus (HCV) is the major etiological agent of both parenterally transmitted and sporadic non-A, non-B hepatitis. The disease is a major health problem with an estimated 50 million people infected worldwide, a high percentage of whom become chronically infected and are at high risk for liver cirrhosis. The serine protease contained within the N-terminal region of the nonstructural protein 3 (NS3 protease) of HCV is considered a promising target for the development of an antiviral therapy. A prime requisite to study in detail the biochemistry of the protease as well as develop inhibitors is the availability of a fast and sensitive in vitro assay of enzyme activity. However, due to their low kcat/Km values, synthetic peptide substrates based on the natural cleavage sites appear unsuitable for this purpose. We show here that appropriate substrates can be obtained by substituting the scissile amide bond with an ester linkage. The resulting depsipeptides show >100-fold improvement in kcat/Km values, up to 13,000 M-1 s-1, enabling detection of activity with subnanomolar NS3 concentrations. The ester substrates are obtained in high yield entirely by solid-phase synthesis using commercially available materials, without the need for any preassembled building blocks.(c) 1996 Academic Press, Inc.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660572     DOI: 10.1006/abio.1996.0235

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  8 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides.

Authors:  R Zhang; J Durkin; W T Windsor; C McNemar; L Ramanathan; H V Le
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease.

Authors:  Ye Yu; Jing-feng Jing; Xian-kun Tong; Pei-lan He; Yuan-chao Li; You-hong Hu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2014-07-21       Impact factor: 6.150

4.  Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening.

Authors:  Xuemei Yu; Bruno Sainz; Susan L Uprichard
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

5.  Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

Authors:  Diane Thibeault; Christiane Bousquet; Rock Gingras; Lisette Lagacé; Roger Maurice; Peter W White; Daniel Lamarre
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

6.  Establishment of a cell-based assay system for hepatitis C virus serine protease and its primary applications.

Authors:  Hong-Xia Mao; Shui-Yun Lan; Yun-Wen Hu; Li Xiang; Zheng-Hong Yuan
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

7.  Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening.

Authors:  Xuemei Yu; Susan L Uprichard
Journal:  Curr Protoc Microbiol       Date:  2010-08

8.  Simultaneous assay for protease activities of hepatitis C virus and human immunodeficiency virus based on fluorescence detection.

Authors:  Tsutomu Kabashima; Keiko Tonooka; Makoto Takada; Masaaki Kai; Takayuki Shibata
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.